创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Characterization of Car-T-MHC/KO Therapy Evaluation Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-07 14:00
  • Views:

(Summary description)InnoModels' Car-T-MHC/KO therapy evaluation platform is a major breakthrough in the field of cancer immunotherapy in recent years. Based on sophisticated engineering technology, the platform provides a new treatment option for cancer patients by creating highly efficient and safe Car-T cells, which not only has significant anti-cancer effects, but also has an expanding application scope, bringing hope for the treatment of other immune-related diseases. The following is a detailed analysis of the features of the evaluation platform of InnoModels' Car-T-MHC/KO therapy

InnoModels: Characterization of Car-T-MHC/KO Therapy Evaluation Platform

(Summary description)InnoModels' Car-T-MHC/KO therapy evaluation platform is a major breakthrough in the field of cancer immunotherapy in recent years. Based on sophisticated engineering technology, the platform provides a new treatment option for cancer patients by creating highly efficient and safe Car-T cells, which not only has significant anti-cancer effects, but also has an expanding application scope, bringing hope for the treatment of other immune-related diseases. The following is a detailed analysis of the features of the evaluation platform of InnoModels' Car-T-MHC/KO therapy

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-07 14:00
  • Views:
Information

InnoModels' Car-T-MHC/KO therapy evaluation platform is a major breakthrough in the field of cancer immunotherapy in recent years. Based on sophisticated engineering technology, the platform provides a new treatment option for cancer patients by creating highly efficient and safe Car-T cells, which not only has significant anti-cancer effects, but also has an expanding application scope, bringing hope for the treatment of other immune-related diseases. The following is a detailed analysis of the features of the evaluation platform of InnoModels' Car-T-MHC/KO therapy.
Personalized Treatment Strategy
InnoModels' Car-T technology emphasizes personalized treatment, which is one of its biggest technical highlights. Traditional cancer treatment often adopts a one-size-fits-all strategy, making it difficult to provide precise treatment for patients' specific conditions. Car-T technology, on the other hand, customizes the Car-T treatment plan through in-depth study of the patient's genetic information, thus improving the relevance and effectiveness of the treatment. This personalized treatment strategy not only helps to improve the survival rate and quality of life of patients, but also reduces unnecessary side effects and makes the treatment process safer and more comfortable.
Wide range of treatments
InnoModels' Car-T-MHC/KO therapeutic evaluation platform not only focuses on cancer treatment, but also extends the application of the technology to other immune-related diseases. Car-T technology, as a kind of immunotherapy, can be used to activate a patient's own immune system to attack tumor cells, and therefore has a wide range of application prospects. In addition to cancer, the platform can also be applied to autoimmune diseases, infectious diseases and other areas, bringing hope to more patients.

 


Precise Efficacy Assessment
In order to ensure the effectiveness of Car-T therapy, InnoModels' Car-T-MHC/KO therapy evaluation platform provides an accurate efficacy assessment system. By closely monitoring and analyzing the indicators of patients before and after treatment, the platform can accurately assess the effectiveness of Car-T treatment, so as to timely adjust the treatment plan and ensure that patients get the best treatment results. This precise efficacy assessment system not only helps to improve the success rate of treatment, but also reduces the pain and financial burden of patients.
Safety Guarantee
During the production of Car-T cells, InnoModels Biotechnology adopts strict quality control measures to ensure the safety and efficacy of the cells. In addition, the platform has conducted a comprehensive assessment of the various potential risks in the treatment process and formulated a comprehensive risk management program. Together, these measures safeguard the safety of Car-T treatment, so that patients can be assured and feel at ease when receiving treatment.
Cutting-edge technology support
InnoModels Biotechnology Car-T-MHC/KO therapy evaluation platform is strongly supported by cutting-edge technologies. The platform adopts the latest bioengineering technology, gene editing technology and data analysis technology to ensure the efficient production of Car-T cells and the precise formulation of personalized treatment plans. The application of these cutting-edge technologies not only improves the success rate of treatment, but also promotes the technological advancement in the field of cancer immunotherapy.
In conclusion, with its personalized treatment strategy, wide therapeutic range, accurate efficacy assessment, safety guarantee and support of cutting-edge technologies, the InnoModels Biotechnology Car-T-MHC/KO Therapy Evaluation Platform provides a brand new treatment option for cancer patients. In the future, with the continuous development and improvement of the technology, the platform is expected to bring benefits to more patients and drive the field of cancer immunotherapy to a new peak.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司